Navigation Links
CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
Date:4/15/2011

nor a solicitation of an offer to sell any securities.  The solicitation and the offer to buy shares of Cardiogenesis Corporation's common stock has been made pursuant to an offer to purchase and related materials that CryoLife, Inc. filed with the Securities and Exchange Commission on April 5, 2011.  Also on April 5, 2011, CryoLife, Inc. filed a tender offer statement on Schedule TO with the Securities and Exchange Commission, and on the same date, Cardiogenesis Corporation filed a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer.  The tender offer statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the solicitation/recommendation statement contain important information that should be read carefully and considered before any decision is made with respect to the tender offer.  These materials, as filed on April 5, 2011, have been sent free of charge to all shareholders of Cardiogenesis Corporation.  In addition, all of these materials (and all other materials filed by CryoLife, Inc. or Cardiogenesis Corporation with the Securities and Exchange Commission, including amendments to these materials) are available at no charge from the Securities and Exchange Commission through its website at www.sec.gov.  Free copies of the offer to purchase, the related letter of transmittal and certain other offering documents are available by CryoLife, Inc. by Suzanne K. Gabbert at 1655 Roberts Blvd., NW, Kennesaw, GA 30144, telephone number 770-419-3355.  Investors and security holders may also obtain free copies of the documents filed with the Securities and Exchange Commission by Cardiogenesis by contacting Cardiogenesis Corporation Investor Relations at 11 Musick, Irvine, CA, 92618, telephone number (949) 420-1827, or IR@Cardiogenesis.com.

Additional Information about the Merg
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
2. David P. Lang Appointed Vice President of CryoLife International, Inc.
3. CryoLife to Present at UBS Global Life Sciences Conference
4. CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
5. CryoLife to Present at UBS Global Life Sciences Conference
6. CryoLife Announces First Clinical Use of BioFoam(R)
7. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
8. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
9. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
10. CryoLife Reports Record First Quarter Revenues of $26.7 Million
11. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... May 4 Environmental Tectonics Corporation,s (NYSE AMEX ... Division announced today the addition of Mr. Ray ... Wyngarden will be responsible for expanding market awareness ... ETC,s other hyperbaric products in the western portion ...
... it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, ... vaccine based on the same Replikins peptide technology which provided the ... was on its way. , ... London, UK (PRWEB) ...
... YORK and NASSAU, The Bahamas, May 1 Fincor ... Prospero Group (Pink Sheets: PRPG) , a leading company ... the new ACTRx Malaria and Dengue fever treatment. Fincor also ... a majority of ACTRx International Inc., which combines several natural ...
Cached Biology Technology:Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 2Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 3H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide 2Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment 2
(Date:4/15/2014)... in nanoparticle form could help reduce side effects by ... years, scientists have developed nanoparticles that deliver one or ... to design particles that can carry any more than ... have devised a new way to build such nanoparticles, ... different drugs. In a paper published in the ...
(Date:4/15/2014)... cuttlefish, squid and octopus has uncovered details of ... they may help in investigating populations of their ... 10 new parasite species− dicyemid mesozoans −, which ... and octopus). They are the very first ... , "Although dicyemid parasites have been studied ...
(Date:4/14/2014)... swallow, but if you,re over 24 years of age ... cognitive motor performance, according to a new Simon Fraser ... doctoral student, associate professor Mark Blair, Thompson,s thesis supervisor, ... student, deliver the news in a just-published PLOS ... the first social science experiments to rest on big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Bizarre parasite may provide cuttlefish clues 2Study says we're over the hill at 24 2
... research has found that hurricane activity is ,clustered, rather ... ecosystems and human population. The research was carried ... Queensland Global Change Institute and School of Biological Sciences, ... Fellow) at the University of Exeter,s Exeter Climate Systems ...
... multi-disciplinary 5-year project at the University of Nevada, Reno ... $10 million in funding from the National Institutes of ... manipulate the communication between cells that causes human neurological ... of Medicine, the College of Science and the Department ...
... by researchers at The University of Texas at Austin ... a cure for Alzheimer,s disease and help answer one ... The research, led by Cockrell School of Engineering ... Assistant Professor Jon Pierce-Shimomura, aims to prevent degeneration of ...
Cached Biology News:Clustered hurricanes reduce impact on ecosystems 2$10 million grant supports biological sciences team at University of Nevada, Reno 2$10 million grant supports biological sciences team at University of Nevada, Reno 3Reversing aging 2Reversing aging 3Reversing aging 4
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: